UMB Bank n.a. Sells 15,426 Shares of McKesson Co. (NYSE:MCK)

UMB Bank n.a. trimmed its holdings in shares of McKesson Co. (NYSE:MCK - Free Report) by 73.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,566 shares of the company's stock after selling 15,426 shares during the period. UMB Bank n.a.'s holdings in McKesson were worth $3,172,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of MCK. Wolff Wiese Magana LLC raised its stake in shares of McKesson by 742.9% in the 3rd quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock worth $29,000 after buying an additional 52 shares in the last quarter. MidAtlantic Capital Management Inc. bought a new stake in McKesson in the third quarter worth about $29,000. RPg Family Wealth Advisory LLC acquired a new stake in McKesson in the 3rd quarter valued at about $31,000. ORG Wealth Partners LLC bought a new position in shares of McKesson during the 3rd quarter valued at about $40,000. Finally, Bruce G. Allen Investments LLC grew its stake in shares of McKesson by 51.9% in the 4th quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company's stock worth $47,000 after purchasing an additional 28 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Leann B. Smith sold 579 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the transaction, the executive vice president now directly owns 864 shares of the company's stock, valued at approximately $494,890.56. This trade represents a 40.12 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.11% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MCK. Leerink Partners reduced their target price on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Citigroup reduced their price objective on McKesson from $713.00 to $677.00 and set a "buy" rating for the company in a research note on Friday, January 10th. Robert W. Baird raised McKesson from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Morgan Stanley increased their price target on McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research report on Tuesday, December 17th. Finally, Wells Fargo & Company upped their price objective on shares of McKesson from $535.00 to $641.00 and gave the company an "equal weight" rating in a research note on Friday, December 13th. Two analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $646.14.

McKesson Stock Down 1.2 %

Shares of NYSE:MCK traded down $7.06 during trading on Tuesday, reaching $585.51. 986,257 shares of the company traded hands, compared to its average volume of 676,463. McKesson Co. has a 1-year low of $464.42 and a 1-year high of $637.51. The firm has a market cap of $74.32 billion, a P/E ratio of 30.32, a price-to-earnings-growth ratio of 1.28 and a beta of 0.52. The firm has a fifty day simple moving average of $594.65 and a 200 day simple moving average of $561.08.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $7.07 EPS for the quarter, beating analysts' consensus estimates of $6.88 by $0.19. McKesson had a negative return on equity of 207.50% and a net margin of 0.77%. The firm had revenue of $93.65 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same quarter in the previous year, the company posted $6.23 earnings per share. The business's quarterly revenue was up 21.3% compared to the same quarter last year. As a group, research analysts anticipate that McKesson Co. will post 32.73 EPS for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date was Monday, December 2nd. McKesson's dividend payout ratio (DPR) is presently 14.71%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.